• Home
• About Us
  • Overview
  • Management
  • Board of Directors
  • Dynavax Europe
  • Careers
• Pipeline
  • Overview
  • Hepatitis B Vaccine
  • Hepatitis C
  • Hepatitis B
  • Asthma
  • Autoimmunity / Inflammation
  • Flu Vaccine
• Partners
• Technology
  • Immune System
  • ISS
  • IRS
  • Publications
• Investors
  • Overview
  • News & Events
  • Stock Information
  • Analyst Coverage
  • Financials
  • SEC Filings
  • Corporate Governance
  • Contact Us
• Contact Us

Dynavax Presents Additional Phase 3 Data for HEPLISAV at DDW Medical Conference
June 3, 2009

Dynavax Announces Data Presentations at American Thoracic Society Medical Conference
May 18, 2009

Dynavax Awarded Grant to Support Development of TLR Inhibitors of Skin Disease
May 13, 2009

Dynavax Presents Data From Novel Universal Flu Vaccine Candidate
April 30, 2009

Dynavax Announces First Quarter 2009 Results
April 28, 2009

Dynavax Presents Additional Phase 3 Data for HEPLISAV at EASL
April 27, 2009

More...

Our diversified pipeline includes 3 clinical product candidates and 3 candidates advancing into the clinic. More...

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates.  Our focus is on serious medical needs in the area of infectious, respiratory, autoimmune and inflammatory diseases.  

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Novartis, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.